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Introduction
Human cells encode  70 Rab GTPases that are localized to 
distinct membrane-bound compartments (Pereira-Leal and 
  Seabra, 2000, 2001; Colicelli, 2004). These proteins regulate 
transport vesicle formation, motility, docking, and fusion via 
interaction with so-called effector proteins that bind with 
  preference to Rabs in their GTP-bound conformations (Zerial 
and McBride, 2001). The number of identifi  ed Rab effector pro-
teins is growing steadily, yet little is known about how Rabs are 
localized correctly within cells (Pfeffer and Aivazian, 2004).
COOH-terminal prenylation contributes to the stable mem-
brane association of Rab proteins. Rabs also interact with numer-
ous effectors to form microdomains on organelle surfaces (Zerial 
and McBride, 2001). For example, Rab5 binds to early endosome 
antigen-1 (EEA1), which binds to early endosomes via Rab5 
and also by binding to phosphatidylinositol-3-phosphate. Rab5 
recruits the kinase that generates this lipid, thereby catalyzing the 
generation of a membrane microdomain. The Rab9 GTPase 
  recruits a cytosolic protein, tail-interacting protein of 47 kD 
(TIP47), which binds both to Rab9 and to the cytoplasmic do-
mains of two mannose 6-phosphate receptors (MPRs; Pfeffer, 
2003). In both cases, combinatorial recognition of a Rab and 
a membrane constituent enhances the selective recruitment of a 
cytosolic effector protein. Thus, there are many examples of Rabs 
that serve as determinants of effector–membrane binding.
But how are Rabs themselves localized? Prenylated Rabs 
are delivered to membranes by a protein named GDP dissocia-
tion inhibitor (GDI; Pfeffer and Aivazian, 2004). Complexes of 
Rabs bound to GDI bear all of the information needed to ac-
complish their specifi  c membrane delivery (Soldati et al., 1994; 
Ullrich et al., 1994). Proteins called GDI displacement factors 
(GDFs) may facilitate Rab recruitment; e.g., Yip3 protein was 
recently shown to be able to release Rab9 from GDI and lead to 
its membrane association (Sivars et al., 2003). But Yip3 is not 
a Rab receptor, and it acted catalytically to permit Rab9 to asso-
ciate with membranes. Yip3 catalyzes the release of endocytic, 
but not exocytic, Rabs from GDI (Sivars et al., 2003). Thus, 
  although GDFs likely contribute to Rab delivery, we know little 
about how they distinguish between Rab types or the breadth 
of their substrate recognition. Their partial specifi  city cannot 
by   itself, explain the sequestration of this category of Rabs 
into early endosomes, recycling endosomes, or late endosomes. 
Moreover, steady-state localization of Rab proteins is likely to 
include interactions of Rabs with other constituents, after they 
are delivered to a membrane surface.
Early work on Rab localization suggested that COOH-
  terminal Rab hypervariable domains specifi   ed their distinct 
  localizations (Chavrier et al., 1991; Brennwald and Novick, 
1993; Stenmark et al., 1994). But more recent analyses suggest 
a more complex scenario. Ali et al. (2004) found that several 
Rabs were correctly localized, despite bearing signifi  cant al-
terations in their hypervariable domains. As described herein, 
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we obtained similar fi  ndings for a different set of Rab chimeras, 
and we used this as a starting point to explore the mechanisms 
of Rab localization.
In this study, we present evidence that certain effectors 
may play a special role in Rab9 localization. Hints of this came 
from a recent study in which the Rab9 effector TIP47 was de-
pleted from cells using RNAi (Ganley et al., 2004). Loss of 
most of the predominantly cytosolic TIP47 protein led to the 
destabilization of Rab9; its half-life decreased from 32 to 8 h. 
This was unexpected, because we think of prenylated Rabs as 
independent entities residing on organelle surfaces or as a com-
plex with GDI in the cytosol. We show that TIP47 is a “key” 
  effector, in that it controls Rab9 stability (Ganley et al., 2004), 
as well as its steady-state localization. In addition, TIP47 can 
compete with Rab1 and Rab5 effectors to relocalize Rab1 and 
Rab5 chimeras to late endosomes.
Results
We generated and purifi  ed hypervariable domain chimeras based 
on late endosome–localized Rab9, early endosome–  localized 
Rab5, and Golgi-localized Rab1 (Fig. 1). The hypervariable 
  domain junction was selected based on sequence alignments 
(Chavrier et al., 1990; Pereira-Leal and Seabra, 2000) and on 
the three-dimensional structures of Rab3A (Ostermeier and 
Brunger, 1999), Rab5C (Merithew et al., 2001), and Rab9 
(Chen et al., 2004). Junctions were placed near the end of helix 
5 at a dibasic repeat that is conserved in Rab9, Rab5, and Rab1 
  sequences (Fig. 1 A, blue residues). Most of the hypervariable 
domain is unstructured and extends beyond the GTPase fold 
(and is not included in the structures shown). By splicing 
  sequences at or near the end of the structured portion, we hoped 
to avoid signifi  cant alterations in Rab structure.
When expressed as GFP fusions in cells, the chimeras 
were effi  ciently prenylated (Fig. 2, A and B). In all cases, pre-
nylation effi  ciency was  50%, as determined by comparative 
analysis of membrane and cytosolic fractions (Fig. 2, A and B). 
Membrane-associated forms migrated at a different mobility 
upon SDS-PAGE, which is consistent with prenylation. This 
suggests that the chimeras were folded well enough to be recog-
nized by Rab prenyltransferase.
In addition, all of the purifi  ed chimeras were highly active 
for nucleotide binding and, in most cases, effector binding 
Figure 1.  Rab chimeras studied. (A) Ribbon diagrams of the Rab5c-
GppNHp (residues 19–182, left; Merithew et al., 2001) and Rab9-GDP 
(residues 2–175, right; Chen et al., 2004) structures (Pettersen et al., 
2004). The so-called complementarity determining regions that are be-
lieved to be important for effector interaction (Ostermeier and Brunger, 
1999) are highlighted in red. The ﬁ   rst conserved basic residue that 
was used as the site of hypervariable domain exchange is highlighted in 
blue; the presumed Rab switch regions (Ostermeier and Brunger, 1999; 
Merithew et al., 2001) are highlighted in yellow. (B) Diagrams of the 
  hypervariable domain chimeras described herein. Residue numbers indi-
cate composition of the constructs; Rabs differ in length at both NH2 and 
COOH termini, so the junction numbers differ and are shown to represent 
the precise junction identities from the parental Rab sequences.
Figure 2.  Chimeric Rabs are prenylated and active for GTP binding. 
(A and B) Analysis of GFP-Rab membrane association in HeLa cells. HeLa 
cells were transiently transfected for GFP-Rab expression, and lysates were 
separated into membrane and cytosol fractions for analysis by SDS-PAGE 
and anti-GFP immunoblot. Bands shown in A were quantitated by ImageJ 
for display in B. (C) Nucleotide (GTPγS) binding to recombinant, puriﬁ  ed 
GST-Rabs. Rabs were incubated with radiolabeled GTPγS, and the extent 
of binding was quantitated by nitrocellulose ﬁ  lter binding and scintillation 
counting. Error bars represent the SEM.TIP47 AND RAB9 LOCALIZATION • AIVAZIAN ET AL. 919
(Figs. 3 and 4 and Table I), which are both important tests of 
proper protein folding. Fig. 2 C shows the ability of the purifi  ed 
GST chimeras to bind radiolabeled GTP in a nucleotide ex-
change reaction. On average, these chimeras were  75% active 
in terms of their abilities to release bound GDP and to bind 
added GTP. Although there was slight variability between each 
purifi  ed Rab protein preparation, the 20% maximum differences 
observed could not account for the differences in effector binding 
shown in Figs. 3 and 4.
Fig. 3 shows the ability of each of the chimeras to bind to 
the Rab9 effectors TIP47 (Diaz and Pfeffer, 1998; Carroll et al., 
2001) and p40 (Diaz et al., 1997).  Pure, nonepitope-tagged Rab 
proteins were prebound to [
35S]GTPγS; unbound nucleotide 
was removed by gel fi  ltration, and the active proteins were incu-
bated with His-tagged effectors, and then immobilized on an 
Ni-NTA resin. As expected, Rab9 bound specifi  cally to TIP47 
and p40; Rab1 and Rab5 showed very low binding ability (Fig. 3, 
A and B). The Rab9 hypervariable domain was required both 
for TIP47 and p40 binding, as neither Rab9/1 (Fig. 3 A) nor 
Rab9/5 (Fig. 3 B) bound signifi  cantly to either effector (Fig. 3). 
Surprisingly, Rab5/9 and Rab1/9 bound well to Rab9 effectors 
compared with the parental Rabs 1 and 5. Therefore, the Rab9 
hypervariable domain is not only required for binding TIP47 
and p40, but it is also suffi  cient for Rab9 effector binding (espe-
cially to TIP47) within the context of a Rab GTPase structure.
Although the hypervariable domain was suffi  cient  for 
TIP47 binding to Rab5/9 and Rab1/9 chimeras, binding also 
  required the presence of a GTPase domain. This was clear from 
experiments in which we tested the nucleotide dependence of 
the interaction (Fig. 3 C). For both Rab5/9 and Rab1/9, inter-
action with TIP47 showed the same nucleotide dependence of 
binding that is seen with Rab9 (Fig. 3 C), with a preference for 
the GTP-bound state. Thus, interaction with TIP47 requires 
more than just the Rab9 hypervariable domain, and likely 
  involves the switch domains of Rab5/9 and Rab1/9, as these 
  domains are the only parts of a Rab that change conformation 
between GTP- and GDP-bound states. In addition, Rab recogni-
tion by p40 appears to require more signifi  cant interaction with 
nonhypervariable domain sequences than Rab protein recogni-
tion by TIP47.
The same Rab proteins were next tested for binding 
to the Rab5 effectors rabaptin-5 (Stenmark et al., 1995) and 
Figure 3.  The Rab9 hypervariable domain is necessary 
and sufﬁ  cient for Rab9 effector binding. (A) Binding of 
  puriﬁ  ed, untagged Rab9, Rab1A, Rab9/1, and Rab1/9 
to the Rab9 effectors His6-TIP47(152–434; closed bars) 
and His6-p40 (open bars). Data are normalized relative to 
the binding seen for parental Rabs. (B) Same as in A, with 
untagged Rab9, Rab5a, Rab9/5, and Rab5/9. (C) Binding 
of [
35S]GTPγS- and [
3H]GDP-loaded Rab9, Rab5/9, and 
Rab1/9 to His6-TIP47(152–434). 100% binding to p40 
or TIP47 represented 3.9 or 1.5 pmol Rab9, respectively, 
in A and B. This assay measures active Rab molecules 
only; untagged Rab proteins were all  100% active, except 
for Rab9/5, which contained  30% active molecules. 
  Error bars represent the SEM.
Figure 4.  Some, but not all, Rab1 and Rab5 
effectors require hypervariable domain se-
quences for binding. (A) Binding of GST ver-
sions of Rab9, Rab5, Rab9/5, and Rab5/9 
to Rab5 effectors EEA1 and rabaptin-5 from 
cytosol. (B) Binding of GST versions of Rab9, 
Rab1, Rab9/1, and Rab1/9 to Rab1 effectors 
GM130, golgin-84, and p115 from rat liver 
Golgi detergent extracts. Data are normalized 
relative to the binding seen for parental Rabs. 
Error bars represent the SEM.EEA1 (Simonsen et al., 1998; Christoforidis et al., 1999), and 
to the Rab1 effectors GM130, golgin-84, and p115 (Fig. 4; 
Allan et  al., 2000; Moyer et al., 2001; Satoh et al., 2003). 
In contrast to what was observed for Rab9 effector interactions, 
Rab5 binding to two of its effectors did not require Rab5 
  hypervariable domain sequences. As shown in Fig. 4 A, GST-
Rab5, but not GST-Rab9, bound to the Rab5 effectors EEA1 
and rabaptin-5 from bovine brain cytosol. GST-Rab5/9 was 
fully functional for binding both proteins, whereas active GST-
Rab9/5 did not bind either effector. These data confi  rm that the 
Rab5 hypervariable domain is neither required nor suffi  cient 
for EEA1 (Merithew et al., 2003) or rabaptin-5 interaction. The 
published structure of COOH-terminal–truncated (and hyper-
variable domain–truncated) Rab5 bound to the coiled coil 
region of rabaptin-5 (Zhu et al., 2004) is consistent with the 
hypervariable domain independence of rabaptin-5 binding 
shown in this study.
Rab1 effector binding was studied using GST-Rab pro-
teins and detergent-extracted rat liver Golgi membranes as an 
effector protein source (Fig. 4 B). As with the Rab5 effectors 
rabaptin-5 and EEA1, GM130 did not require the Rab1 hyper-
variable domain for binding, as it bound well to both GST-Rab1 
and GST-Rab1/9 (Fig. 4 B). In contrast, the Rab1 hypervariable 
domain was more important for binding to both golgin-84 and 
p115 (Fig. 4 B). Rab1/9 failed to bind p115, and showed weaker 
binding to golgin-84. Although the Rab9 hypervariable domain 
was suffi  cient for TIP47 and p40 interaction (Fig. 3, A and B), 
the Rab1 hypervariable domain was necessary, but not suffi  -
cient, for golgin-84 and p115 interaction (Fig. 4 B). Therefore, 
these two Rab1 effectors also require nonhypervariable domain 
determinants for Rab recognition. The differences in the Rab-
binding profi  les of GM130, golgin-84, and p115 show that these 
Rab1 effectors rely, to different extents, on distinct binding 
  determinants in the Rab1 structure.
We determined the intracellular localizations of each 
of the chimeras as GFP-fusions in mammalian cells; the 
  results are summarized in Table I. Rab5/9 was clearly present 
in early endosomes, as judged by colocalization with EEA1 
(Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.
200510010/DC1). Very little Rab5 or Rab5/9 was present in late 
endosomes (Fig. S2).
For the chimeras studied, the Rab5 hypervariable do-
main was dispensable for both effector binding (Fig. 4 A) and 
for early endosome localization (Fig. 5; Fig. S2). Rab5/9 and 
Rab5/7 (not shown) were present on numerous   peripheral 
early endosomes, many located near the plasma membrane 
(Fig. 5 A; Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200510010/DC1).
Quantitation of Rab5/9 colocalization with endogenous 
EEA1, which is a marker for early endosomes, confi  rmed that 
Rab5/9 has a localization profi  le identical to that of Rab5. 71% 
of EEA1-positive structures contained exogenous Rab5/9; in a 
parallel experiment, 74% of EEA1 structures contained exogenous 
Figure 5.  Colocalization of Rab5/9 with EEA1. (A) Colocalization of CFP-
Rab5/9 with the early endosome marker EEA1 in ﬁ  xed HeLa cells stained 
with anti-EEA1 and anti-GFP antibodies. The square in A is enlarged for both 
markers (right); arrows are included to facilitate comparison. Bar, 10 μm. 
(B) Quantitation of CFP-Rab5/9, CFP-Rab5, and YFP-Rab9 colocalization. 
Venn diagrams are shown as follows: CFP-Rab5/9, CFP-Rab5, and 
YFP-Rab9 versus EEA1; CFP-Rab5/9 and CFP-Rab5 versus endocytosed 
anti–CI-MPR IgG; and CFP-Rab5/9 and CFP-Rab5 versus YFP-Rab5. The 
number of positive structures is indicated below each protein name; overlap 
is indicated as described in the Results section. 
Table I. Rab effector binding correlates with localization
Rab Localization Rab9
effector
binding
Rab5
effector
binding
Rab1
effector
binding
Rab9 Late endosomes +− −
Rab9/5 Golgi
1,2 −− nd
Rab9/1 Golgi
1,3 − nd −
−
Rab5 Early endosomes −+ nd
Rab5/9 Early endosomes
4–6 ++ nd
Rab1 Golgi − nd +
Rab1/9 Golgi
1,7 + nd +
GM130,
Golgin-84
Localizations of CFP- or YFP-tagged Rab chimeras were determined in HeLa 
cells by comparison with endogenous organelle markers, and in Bs-C-1 cells by 
comparison with overexpressed CFP- or YFP-tagged Rab GTPases or CFP-Golgi. 
Markers (superscripted in table) were as follows: 1, p115; 2, CFP-galacto-
syltransferase; 3, anti-TGN46; 4, CFP-Rab5; 5, anti-EEA1; 6, anti-rabaptin-5; 
7, CFP-Rab1. nd, no data.
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tures contained exogenous Rab9 (Fig. 5 B).
Rab5/9 and Rab5 colocalized signifi   cantly when co-
expressed; 86% of CFP-Rab5/9–positive structures (1,384/1,618) 
were also positive for YFP-Rab5. Given 85% colocalization 
  between coexpressed CFP- and YFP-Rab5 in control experi-
ments (Fig. 5 B), we conclude that Rab5/9 shows identical 
  localization to Rab5. Finally, Rab5/9 was not found on late 
  endosomes any more than Rab5 was, as both Rabs showed low 
colocalization (11 and 12%, respectively) with endocytosed 
anti–cation-independent (CI) MPR (CI-MPR) IgG that had 
been chased into late endosomes (Fig. 5 B).
These data demonstrate that the Rab5 hypervariable 
  domain is dispensable for the early endosome localization of 
Rab5/9. A lack of a requirement for certain hypervariable domain
  sequences has also been reported by Ali et al. (2004). Together, 
these data confi  rm that Rab targeting is more complex than 
originally believed.
In contrast to Rab5, the Rab9 hypervariable domain was 
required for late endosome localization. Replacement of the 
Rab9 hypervariable domain in Rab9/5 and Rab9/1 chimeras 
disrupted late endosome targeting and relocalized both proteins 
to the Golgi (Table I). Rab9/5 and Rab9/1 were clearly Golgi 
localized, as determined by their colocalization with p115, but 
not with endocytosed anti–CI-MPR antibody, in late endosomes 
(Fig. S1). The Golgi localization of Rab9/5 was not expected if 
hypervariable domain sequences were key; the protein should 
have been present on early endosomes. Although it has been 
proposed that the ER and Golgi may be sites for Rab mislocal-
ization (Ali et al., 2004), we favor an alternative  possibility. This 
laboratory has recently identifi  ed two new Rab9 effectors that 
are localized at the TGN. It is possible that one of these   proteins 
Figure 6.  TIP47 binding to Rab5/9 triggers relocaliza-
tion from early to late endosomes. (A) Wide-ﬁ  eld  light 
microscopy. GFP-Rab5/9 localization in ﬁ  xed HeLa cells 
(left). The overexpression of wild-type TIP47 (middle), but 
not of mutant TIP47
SVV-AAA (Hanna et al., 2002), which 
is deﬁ  cient for Rab9 binding (right), causes GFP-Rab5/9 
localization to perinuclear late endosomes. (middle) The 
cell is outlined in white. Levels of TIP47 wild-type and mu-
tant protein overexpression were approximately ninefold. 
(B) TIP47-relocalized perinuclear Rab5/9 is present on 
late endosomes. Deconvolution microscopy of cells over-
expressing TIP47 protein; perinuclear GFP-Rab5/9 colo-
calized with late endosomal, endocytosed anti–CI-MPR
antibody. (C) Deconvolution microscopy shows TIP47-
relocalized perinuclear Rab5/9 is not present on the Golgi, 
as it did not colocalize with the Golgi marker p115. In the 
merge images in B and C, Rab5/9 is shown in green, 
whereas the organelle markers are shown in red. In B 
and C, the TIP47 is shown as the mean of the summation 
of total Z-sections; other images are 0.2-μm Z-sections. 
Bars: (A) 10 μm; (B and C) 5 μm.
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interacts with Rab9/5 preferentially and retains the protein 
at that site. The Golgi localization of Rab9/1 may also be attrib-
utable to its hypervariable domain, as at least one Rab1-binding
protein recognizes Rab1 hypervariable domain sequences 
 (Preisinger et al., 2005). Rab1 contains effector binding information 
in nonhypervariable domain sequences (Fig. 4), and   accordingly, 
Rab1/9 localized to the Golgi (Table I and Fig. S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200510010/DC1). 
  Although we cannot yet fully explain the localizations of 
Rab9/5 and Rab9/1, we conclude that the Rab9 hypervariable 
domain is required for proper late endosome localization of the 
Rab9 GTPase.
Competition between effectors 
can relocalize Rab chimeras
These experiments reveal a correlation between effector binding 
and proper subcellular localization (Table I). Yet, the ability 
of a chimera to bind a given effector in vitro was not suffi  cient 
to dictate cellular localization. Rab5/9 and Rab1/9 could bind 
TIP47 (Fig. 2), but were not localized to late endosomes. 
In this regard, it is important to note that endogenous Rab5 
is more than twofold more abundant than Rab9 in HeLa cell 
extracts; 4.2 versus ≥9.4 pmol/mg HeLa cells postnuclear 
  supernatant protein. Rab5 effectors may be present at similarly 
higher levels, and by simple mass action, direct Rab5/9 to 
early endosomes.
The ability of the Rab5/9 protein to interact with both 
Rab5 and Rab9 effectors (Figs. 3 and 4) enabled us to test if 
  effector binding is the primary determinant of Rab localization. 
If effector interaction is key to Rab localization, overexpression 
of the late endosomal Rab9 effector TIP47 should be suffi  cient 
to move Rab5/9 from early (Fig. 5, Fig. 6 A, and Fig. S2) to late 
endosomes. As shown in Fig. 6 A (middle), coexpression of 
GFP-Rab5/9 with wild-type TIP47 relocalized the chimeric 
Rab5/9 to late endosomes. Relocalization required the ability 
of TIP47 to bind Rab9 sequences. Coexpression of a mutant 
TIP47 (TIP47
SVV-AAA) that is defi  cient in Rab9 binding (Hanna 
et al., 2002) failed to relocalize the Rab5/9 protein (Fig. 6 A, 
right). The perinuclear, TIP47-relocalized Rab5/9 chimera was 
present in late endosomes and not the Golgi, as a signifi  cant 
fraction of it colocalized with endocytosed, late endosomal 
anti–CI-MPR antibody (Fig. 6 B), but not the Golgi marker 
p115 (Waters et al., 1992; Fig. 6 C). In contrast, overexpression 
of p40 did not alter the distribution of Rab5/9 from perinuclear 
early endosomes (Supp. Fig. 4 A).
67% of cells displayed an entirely perinuclear staining 
  pattern for Rab5/9 in the presence of wild-type TIP47 (Fig. 6 A, 
middle) compared with <30% in cells expressing Rab5/9 alone. 
This increase is very likely caused by a direct interaction between 
Rab5/9 and TIP47, as only 29% of cells expressing TIP47
SVV-AAA 
showed perinuclear Rab5/9 staining (Fig. 6 A, right). Therefore, 
the interaction of the chimeric Rab with TIP47 was both necessary 
and suffi  cient to drive its steady-state localization.
Rab1/9 also interacted with both Rab1 and Rab9 effec-
tors, although slightly less well than Rab5/9 (Fig. 3 A and 
Fig. 4 B). Therefore, we tested if Rab1/9 could also be relo-
calized from the Golgi (Fig. S3) to late endosomes upon 
TIP47 overexpression (Fig. 7 A).  Indeed, in 75% of cells ex-
pressing low levels of Rab1/9 protein together with exoge-
nous TIP47, we detected colocalization of a portion of Rab1/9 
with late endosomal, endocytosed anti–CI-MPR antibody 
(Fig. 7 A). As with Rab5/9, coexpression of mutant TIP47 
(TIP47
SVV-AAA) failed to relocalize Rab1/9 to late endosomes 
(Fig. 7 B). Perinuclear staining of Rab1/9 in the presence 
of wild-type TIP47 was more punctate than that seen upon 
coexpression with mutant TIP47 (compare Fig. 7 A with B). 
Therefore, even in the context of the nonendosomal Rab1 
  GTPase, binding of TIP47 to the Rab9 hypervariable domain 
was suffi  cient for late endosome relocalization. Little Rab1/9 
colocalized with the TGN marker GCC185 in cells expressing 
TIP47 (Fig. 7 C).
Figure 7.  TIP47 binding to Rab1/9 triggers relocalization from the 
Golgi to late endosomes. (A and B) Deconvolution microscopy shows 
CFP-Rab1/9 (left) and endocytosed anti–CI-MPR antibody (middle) locali-
zations in HeLa cells in the presence of overexpressed wild-type (A) or Rab-
binding–deﬁ   cient mutant (B) TIP47 (right). The bottom images show the 
perinuclear region of the same cell. (C) Deconvolution microscopy shows 
CFP-Rab1/9 (left) and p115 (right) localizations in HeLa cells in the pres-
ence of overexpressed wild-type TIP47 (right). In the merge images, 
Rab1/9 is shown in green, whereas the organelle markers are shown 
in red. TIP47 is shown as the mean of the summation of total Z-section 
  images; other images are 0.2-μm Z-sections. Bars, 5 μm.TIP47 AND RAB9 LOCALIZATION • AIVAZIAN ET AL. 923
It is possible that GDI delivered prenylated Rab1/9 
directly to the endocytic pathway and that it was then stabilized 
there by TIP47 interaction. Alternatively, Rab1/9 may have cycled
from the Golgi through endosomes and been trapped there by 
TIP47. In any event, effector interaction was suffi  cient to dictate 
the steady-state localizations of two different Rab chimeras.
Like Rab5/9, Rab1/9 was not relocalized by overexpression 
of p40 (Fig. S4 B, available at http://www.jcb.org/cgi/content/
full/jcb.200510010/DC1), but remained in a tight,   ribbon-like, 
perinuclear pattern (compare with Fig. S3), in contrast to the 
punctuate, perinuclear pattern of relocalized Rab1/9 protein. 
In addition, although siRNA depletion of TIP47 destabilizes 
Rab9, increasing its half-life from 32 to 8 h (Ganley et al., 
2004), depletion of p40 using RNA interference did not affect
Rab9 degradation (Fig. S4 C). Rab9 half-life was 54 h in 
control cells and 43 h in p40 siRNA-treated cells. Thus, TIP47, 
but not p40, is a key effector for both Rab9 stability and late 
endosome localization.
Discussion
We have presented a test of the ability of Rab effectors to direct 
the localization of Rab proteins to distinct membrane com-
partments. Such an analysis was only possible because of our 
serendipitous generation of two Rab chimeras that were able to 
bind two distinct classes of Rab effector proteins. A Rab5 
  protein containing the Rab9 hypervariable domain (Rab5/9) 
bound well to the Rab5 effectors rabaptin-5 and EEA1, and also 
showed signifi  cant binding to the Rab9 effectors TIP47 and p40. 
Similarly, a chimera comprised of Rab1 linked to the Rab9 
  hypervariable domain bound to the Rab1 effectors GM130 and 
golgin-84. This Rab1/9 hybrid also bound strongly to the Rab9 
effector TIP47 and somewhat less strongly to another Rab9 
  effector, p40. Upon expression in cultured cells, the chimeric 
Rabs localized, together with their Rab backbone parental counter-
parts, on early endosomes and the Golgi complex, respectively. 
Yet, when the Rab9 effector TIP47 was coexpressed, the Rab5/9 
and Rab1/9 chimeras moved to late endosomes, together with 
endogenous Rab9. These data demonstrate that effector binding 
can relocalize a Rab from one membrane compartment to 
  another. Only TIP47 had the capacity to relocalize the Rabs; 
  another Rab9 effector (p40) did not. Thus, certain Rab effectors 
can play a dominant role in Rab9 localization.
Our analyses confi  rmed the importance of Rab9 hyper-
variable domain sequences for interaction with the effector pro-
teins TIP47 and p40; in both cases, this domain was necessary 
and suffi  cient for Rab–effector interaction, within the context of 
a Rab GTPase. A recent study has shown a role for hyper-
variable domain sequences in a Rab–effector interaction; Rab7 
COOH-terminal residues are required for binding to the Rab7 
effector RILP (Wu et al., 2005). In addition, polo-like kinase, 
which is a Rab1-binding protein, interacts with the phosphor-
ylated Rab1 hypervariable domain (Preisinger et al., 2005). 
In the structure of Rab3 bound to Rabphilin-3A, residues in 
α helix 5 that are part of the hypervariable domain contribute 
to the Rab-binding interface (Ostermeier and Brunger, 1999). 
In contrast, two Rab5 effectors and two out of three Rab1 effectors 
that were tested failed to require the presence of hypervariable 
domain sequences for binding. Indeed, in the case of EEA1, 
biochemical experiments ruled out a signifi  cant role for the 
Rab5 hypervariable domain in EEA1 binding (Merithew et al., 
2003). In addition, the crystal structure of Rab5 missing its 
  hypervariable domain with a fragment of rabaptin-5 suggested 
that the hypervariable domain would not contribute to this 
Rab–effector pair (Zhu et al., 2004). Rab5 hypervariable domain 
  sequences may contribute to effector interactions not tested in 
this study, but they were not required for the localization of 
Rab5/9. Thus, for Rab9, hypervariable domain interactions with 
TIP47 do direct localization, which is consistent with the original 
proposals of Chavrier et al. (1991) and Brennwald and Novick 
(1993). For the Rab5/9 and Rab1/9 chimeras, nonhypervariable 
domain–dependent interactions were suffi  cient for their initial 
cellular localizations, which were early endosomes and the 
Golgi complex, respectively.
Our working model for how effectors contribute to Rab 
  localization is shown in Fig. 8.  Rabs are delivered to membranes 
by GDI in their GDP-bound forms (Soldati et al., 1994; Ullrich 
et al., 1994). Release of Rabs from GDI may be catalyzed by 
GDFs (Pfeffer and Aivazian, 2004). If nucleotide exchange occurs, 
the Rab will be able to bind to effectors. This may involve recruit-
ment of cytosolic effectors (Fig. 8, option A) or binding to effec-
tors that are already membrane associated (Fig. 8, option B).
Effector binding often stabilizes a Rab in its GTP-bound 
form, enhancing both Rab–membrane and –effector association. 
Rab guanine nucleotide exchange factors (GEFs) associate with 
Rab effectors (Zerial and McBride, 2001), thus, activation of 
Figure 8.  Model for how effectors contribute 
to membrane localization of Rab proteins. 
GDP-bound Rabs are recruited to membranes 
from cytosolic complexes with GDI through the 
catalytic action of a GDF. A GEF catalyzes nu-
cleotide exchange. Interaction of the Rab-GTP 
with an effector that has been recruited to the 
same membrane by a Rab (option A) or by an 
effector-binding partner (option B) will stabilize 
both the Rab and the effector on the mem-
brane. If not bound to the effector, a GTPase-
activating protein (GAP) can activate the Rab 
to hydrolyze its GTP to GDP, thus, allowing 
for potential membrane extraction of the Rab by GDI. Thus, the Rab GTPase is dependent on its effectors, and vice versa, for stable interaction with the 
membrane. The effector-binding partner need not be a protein and can be particular phospholipids, such as phosphoinositides, that are speciﬁ  c to a given 
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Rabs occurs in the vicinity of specifi  c Rab-binding partners. 
If a Rab is delivered to the wrong compartment, it will not be 
a substrate for nucleotide exchange, and GDI can remove it. 
In this manner, a microdomain can form, containing active Rabs 
bound to an array of effector proteins. Importantly, the overall 
specifi  city of Rab localization is contributed to by multiple com-
ponents, such as GDFs, the proximity of Rab-specifi  c GEFs, and 
subsequent effector interactions. For every Rab, there will be 
  numerous potential effector interactions that will depend upon 
the relative affi  nity and abundance of each effector. These mul-
tiple interactions will contribute to the steady-state localization of 
a Rab that we score by immunofl  uorescence microscopy.
What is the mechanism by which TIP47 stabilizes and 
  localizes Rab9? TIP47 is a predominantly cytosolic protein 
(Diaz and Pfeffer, 1998) that interacts with Rab9 and the cyto-
solic domains of the two MPRs via two distinct binding sites 
(Krise et al., 2000; Orsel et al., 2000; Carroll et al., 2001; Hanna 
et al., 2002; Nair et al., 2003; Burguete et al., 2004). TIP47 
binding to Rab9 enhances its affi  nity for MPR cytoplasmic 
  domains (Carroll et al., 2001). Cytosolic TIP47 occurs as 
a   homohexamer or larger oligomer, and may further oligomerize 
when it is membrane associated (Sincock et al., 2003). Thus, 
a TIP47 hexamer has the capacity to interact with multiple Rab9 
molecules and multiple MPRs. This combinatorial requirement 
for both a Rab and MPR cytoplasmic domains enhances the 
specifi  city of TIP47 membrane association; the protein binds 
preferentially to membranes containing both Rab9 and MPRs.
Once TIP47 has found a membrane containing both Rab9 
and MPRs, it will bind there and drive transport from late endo-
somes to the TGN (Carroll et al., 2001; Hanna et al., 2002). If a 
hybrid Rab is nearby, either as a consequence of GDI-mediated 
delivery or because of membrane traffi  cking events, it has the 
potential to become part of a TIP47–Rab9 microdomain. All 
Rabs are in equilibrium with their own effectors, and TIP47-
mediated localization of the chimeras was only observed when 
it could predominate in relation to Rab1 and Rab5 effectors by 
overexpression in cells. Our ability to relocalize Rab5/9 from 
early to late endosomes and Rab1/9 from the Golgi to late 
 endosomes is most easily explained by a binding competition 
  between Rab5, Rab1, and Rab9 effectors.
The “key” effector concept
We have shown that TIP47, but not p40, can relocalize Rab5/9 
and Rab1/9 to late endosomes. Although TIP47 has the capacity 
to stabilize Rab9 on late endosomes (Ganley et al., 2004), p40 
does not. This has led us to propose that each Rab has its own 
key effectors that are essential for steady-state localization and 
Rab protein stabilization. Key effectors may or may not recog-
nize hypervariable domain sequences; nevertheless, their identi-
ties will be important to determine. This may be facilitated by 
systematic depletion of every Rab effector and monitoring the 
corresponding Rab protein turnover. Such a determination is not 
a trivial matter; Rab5 alone has been estimated to have 30 spe-
cifi  c effector proteins (Zerial and McBride, 2001). It seems 
quite reasonable to us that many (if not most) effectors will lack 
the capacity to localize Rabs, and more than one effector may 
localize a Rab.
Another distinguishing feature of TIP47 is its real 
(although twofold weaker) ability to bind Rab9-GDP (Carroll 
et al., 2001; Ganley et al., 2004). This attribute may contribute 
to Rab9 membrane recruitment because TIP47 may retain Rab9 
on the membrane until a Rab9 GEF is encountered (Fig. 8). 
It will be of interest to learn if other, yet to be identifi  ed, key 
  effectors will share this characteristic. In contrast, p40 shows 
a stronger preference for Rab9-GTP (Diaz et al., 1997) and may 
also interact with PIK-FYVE kinase on earlier endosomal com-
partments (Ikonomov et al., 2003). That interaction may explain 
why p40 failed to relocalize Rab5/9 to late endosomes. We can-
not fully rule out the alternative possibility that p40 failed to 
  relocalize the hybrid Rab proteins because it did not bind the 
chimeras as well as TIP47.
If TIP47 is essential for Rab9 localization on late endo-
somes, TIP47 depletion would be expected to lead to Rab9 
  mislocalization. In previous work, we could only deplete cells 
of 80–90% of total cellular TIP47; under these conditions, the 
fraction of total, remaining TIP47 that was membrane associ-
ated increased compared with control cells. Thus, we could 
never completely deplete cells of membrane-associated TIP47 
without killing them; indeed, TIP47 siRNA treatment led to 
a cellular growth arrest (Ganley et al., 2004). Even if we could 
deplete all TIP47, it is likely that other effector interactions 
could contribute to Rab9 localization; Rabs may have more than 
one key interaction that can provide their membrane-domain 
entry and stabilization.
Once located within either the secretory or endocytic 
pathways, our data suggest that effector-mediated incorporation 
and stabilization within a membrane microdomain underlies 
Rab localization at steady state in eukaryotic cells. Localization 
of a newly delivered Rab requires either the preexistence of 
a microdomain already containing that Rab (into which the new 
Rab becomes incorporated), or de novo formation of a micro-
domain that forms when multiple constituents coalesce and 
  assemble (Zerial and McBride, 2001; Pfeffer, 2003). Indeed, 
  effectors also need Rabs for their membrane association. For 
example, active Rabs recruit p115 (Moyer et al., 2001) onto the 
Golgi. Rab9 recruits TIP47 onto endosomes (Carroll et al., 
2001; Ganley et al., 2004). Other effectors, such as GM130 
and GRASP65, associate with the Golgi in a Rab-independent 
 manner (Short et al., 2005). Together, these data reveal a complex 
interdependence and potential for cooperativity between Rabs 
and effectors for membrane localization and domain stabiliza-
tion. A role for key effectors can easily explain all of the previ-
ously reported localization data for chimeric Rab GTPases.
Materials and methods
Recombinant protein expression and puriﬁ  cation
NH2-terminal His6-tagged p40 (Diaz, et al., 1997), His6-tagged TIP47 
(152–434; Carroll et al., 2001), and Rab9-CLLL (Shapiro et al., 1993) 
were puriﬁ  ed. Human Rab5a, Rab1a, and Rab9/5, Rab5/9, Rab9/1, 
and Rab1/9 were cloned into pET14b (Novagen), for expression in E. coli 
as unprenylated Rabs, or into pGEX-4T1 (GE Healthcare). Rab9-CLLL was 
also cloned into pGEX-4T1. Untagged or GST-tagged Rab1a, Rab5, 
Rab1/9, Rab9/1, Rab5/9, Rab9/5, and Rab9-CLLL were expressed in 
E. coli BL21(DE3) RIL (Stratagene) or Rosetta (Invitrogen) cells and induced 
with 0.5 mM IPTG for 3 h at 37°C (Rab5 and Rab9/1) and 16 h at 25°C TIP47 AND RAB9 LOCALIZATION • AIVAZIAN ET AL. 925
(Rab1a, Rab1/9, and Rab5/9, GST-Rab9CLLL, GST-Rab1a, GST-Rab1/9, 
and GST-Rab9/1), and with 1 mM IPTG for 4 h at 30°C (Rab9/5). Cells 
(6 L) were resuspended in 40 ml of 50 mM Tris-HCl, pH 8.0, 8 mM MgCl2, 
2 mM EDTA, 0.5 mM DTT, 10 μM GDP, and protease inhibitor cocktail 
(Roche; Rab1a, Rab5, Rab9/1, Rab1/9, GST-Rab1a, GST-Rab1/9, GST-
Rab9CLLL, and GST-Rab9/1), or 50 mM MES, pH 6.5, 8 mM MgCl2, 
2 mM EDTA, 0.5 mM DTT, 10 μM GDP, protease inhibitor cocktail (Rab9/5 
and Rab5/9). Cells were lysed using a French press, and lysates were 
centrifuged at 15,000 rpm for 20 min (JA 20 rotor; Beckman Coulter). 
  Homogenates were centrifuged at 55,000 rpm for 30 min (70Ti rotor; 
Beckman Coulter). Supernatants were diluted 10-fold with lysis buffer and 
loaded onto a 25-ml Q–Sepharose Fast Flow column (GE Healthcare; 
Rab1a, Rab5, Rab1/9, Rab9/1, Rab9/5, GST-Rab1a, GST-Rab1/9, GST-
Rab9CLLL, and GST-Rab9/1), or a SP–Sepharose Fast Flow column 
(GE Healthcare; Rab5/9). With Rab5, Rab9/5, Rab5/9, Rab1/9, and 
Rab9/1, proteins were eluted with 0–400 mM NaCl in lysis buffer. With 
Rab5, Rab1/9, and Rab9/5, fractions were precipitated with 60% (Rab5) 
or 40% (Rab1/9, Rab9/5, GST-Rab1a, GST-Rab1/9, GST-Rab9CLLL, and 
GST-Rab9/1) (NH4)2SO4, resuspended in buffer A (20 mM Hepes, 
pH 7.4, 200 mM NaCl, 1 mM MgCl2, 0.5 mM DTT, and 10 μM GDP) and 
loaded onto a Superdex 200 column (GE Healthcare). Pools were brought 
to 10% (vol/vol) glycerol and stored at −80°C. With Rab9/1 and Rab5/9, 
fractions were pooled and 4 ml loaded onto a Superdex 200 column. With 
Rab1a, the Q–Sepharose ﬂ  ow-through was subjected to 60% (NH4)2SO4 
precipitation, and the precipitate was resuspended in buffer A. GST-Rab5, 
GST-Rab5/9, and GST-Rab9/5 were expressed and puriﬁ  ed on glutathione–
Sepharose beads (GE Healthcare), as recommended by the manufacturer. 
Rab nucleotide-binding activity was performed as previously described 
(Shapiro et al., 1993), except for nucleotide exchange; Rabs (200 nM) 
were incubated in 50 mM Hepes, pH 7.5, 150 mM KCl, 2 mM EDTA, 
1 mM MgCl2, 0.1% BSA, and 2 μM [
35S]GTPγS (4 nCi/μl) for 
45 min at 25°C in 50 μl of extract.
TIP47 binding to wild-type and chimeric Rab GTPases
Rab proteins (2.6 μM) were preloaded with 3 μM [
35S]GTPγS or [
3H]GDP 
(4.5 nCi/μl) in 2.2 ml of extract containing 50 mM Hepes, pH 7.4, 150 mM 
KCl, 15 mM imidazole, 4.5 mM EDTA, 5 mM MgCl2, 0.5 mM DTT, and 
100 μg/ml BSA. Rab-GTPγS was separated from free nucleotide by gel 
  ﬁ  ltration (G-25). TIP47-binding reactions (450 μl) were in 50 mM Hepes, 
pH 7.4, 150 mM KCl, 15 mM imidazole, 5 mM MgCl2, and 100 μg/ml 
BSA. Rab–[
35S]GTPγS complex (571 nM) was incubated with TIP47 
(2.5 μM) at room temperature for 1.5 h. TIP47-bound Rabs were   recovered 
on Ni-NTA resin (QIAGEN; 50 μl of a 50% slurry) and counted.
p40 binding to Rab GTPases
Rab–[
35S]GTPγS complexes (571 nM) were incubated with 2.5 μM p40 
at room temperature for 1.5 h in 50 mM Hepes, pH 7.4, 150 mM KCl, 
25 mM imidazole, 5 mM MgCl2, and 100 μg/ml BSA. p40-bound 
  GTPases were recovered on Ni-NTA resin (QIAGEN; 50 μl of a 50% slurry) 
and counted.
Rab5 effector binding to Rab GTPases
GST-Rab fusion proteins (3.0 μM) were incubated in binding buffer (20 mM 
Hepes, pH 7.5, 100 mM NaCl, 4.5 mM MgCl2, 5 mM EDTA, 300 μM 
GTPγS, and 0.2 mM DTT) for 1.5 h at room temperature in 200 μl of 
  extract. Bovine brain cytosol (40% (NH4)2SO4 precipitate; 200 μl of 
 15 mg/ml) in binding buffer (+ 1 mM PMSF, 5 mM MgCl2 and protease 
inhibitor cocktail, but no EDTA) was added at 20°C for 1 h. Glutathione–
Sepharose (GE Healthcare; 10% slurry in binding buffer) was added for 
20 min on a rotator. Beads were washed three times with 1 ml of wash buffer 
(20 mM Hepes, pH 7.5, 100 mM NaCl, 5 mM MgCl2, and 0.2 mM DTT). 
Proteins were eluted with SDS-PAGE loading buffer and analyzed by 
immuno  blot with anti-EEA1 and anti–rabaptin-5.
Rab1 effector binding to Rab GTPases
Binding of Rab1 effectors from rat liver Golgi extracts to GST-Rabs was 
measured as previously described (Satoh et al., 2003), with minor modiﬁ  -
cations. In brief, 10 nmol ( 0.5 mg) of each GST-Rab was loaded on 
  glutathione–Sepharose. Bead-bound GST-Rab1 and GST-Rab1/9 were 
loaded with GTPγS (Christoforidis et al., 1999), whereas GST-Rab9CLLL 
and GST-Rab9/1 were loaded with GTPγS in 20 mM Hepes, pH 7.4, 
150 mM KCl, 5 mM EDTA, 4.5 mM MgCl2, 1 mM DTT, and 100 μM 
GTPγS for 1.5 h at room temperature, followed by a 30-min incubation in 
20 mM Hepes, pH 7.4, 100 mM NaCl, 5 mM MgCl2, and 100 μM GTPγS 
at room temperature. Golgi extracts were made by diluting rat liver Golgi 
membranes to 0.5 mg/ml with 20 mM Hepes, pH 7.4, 100 mM KCl, and 
5 mM MgCl2, and adding 1% Triton X-100, 1 mM DTT, protease inhibitor 
cocktail (Roche), 1 mg/ml soybean trypsin inhibitor, and MgCl2 to a ﬁ  nal 
concentration of 8 mM. After incubation on ice for 30 min, extracts were 
spun at 16,000 g for 20 min. 1 mM GTPγS was added to the supernatant. 
Extract (200 μl) was incubated with GST-Rab–loaded beads for 1 h at 4°C. 
Beads were washed, eluted, and analyzed by SDS-PAGE and Western 
blot, as previously described (Satoh et al., 2003).
Chimeric Rab localizations
cDNAs for canine Rab9a and human Rab5a, Rab1a, and Rab9/5, 
Rab5/9, Rab9/1, and Rab1/9 were cloned into pECFP-C1, pEYFP-C1, 
and pEGFP-C3 (CLONTECH Laboratories, Inc.) for expression. For ﬁ  xed 
cell indirect immunoﬂ  uorescence, HeLa cells were grown and transfected 
on glass coverslips. Cells were transfected (Fugene 6; Roche); 16–24 h 
after transfection, cells were ﬁ  xed, permeabilized, and stained (Ganley, 
et al., 2004), and then mounted in ProFade mounting medium (Invitrogen). 
Micrographs in Figs. 6 and 7 and Figs. S1–S4 were acquired using a 
  deconvolution microscopy system (Spectris; Applied Precision, LLC) with an 
inverted epiﬂ   uorescence microscope (IX70; Olympus), a PlanApo 60×, 
1.40 NA, oil immersion objective (Olympus), a charge-coupled device 
(CCD) camera (CoolSNAP HQ; Roper Scientiﬁ   c), and acquisition and 
deconvolution software (DeltaVision; Applied Precision, LLC). Micrographs 
in Fig. 5 were acquired using a microscope (Axioplan2; Carl Zeiss 
  MicroImaging, Inc.) ﬁ  tted with 63×, 1.30 NA, and 100×, 1.3 NA, Plan 
  Neoﬂ  uar objective lenses, a CCD camera (AxioCamHRc; Carl Zeiss Micro-
Imaging, Inc.), and controlled by Axiovision 4.2 software (Carl Zeiss 
  MicroImaging, Inc.). Pictures were analyzed using ImageJ (National Insti-
tutes of Health) and Photoshop (Adobe) software. For late endosome labeling, 
cells were incubated with 30 μg/ml of mouse anti–CI-MPR (2G11) IgG 
with a 20-min pulse and a 40-min chase in complete medium. Endogenous 
organelle markers used were as follows: anti-p115 (Golgi; gift from 
G. Waters, Merck Research Laboratories, Rahway, NJ), anti-TGN46 (TGN; 
Serotec), anti-EEA1 and anti-rabaptin-5 (early endosomes; BD Biosciences), 
and CI-MPR (primarily late endosomes; Diaz and Pfeffer, 1998). Rabbit 
anti-GFP and secondary antibodies derivatized with Alexa Fluor dyes 
  (Invitrogen) were used. The extent of colocalization between endosomal 
Rabs and organelle markers was quantitated by generating contour maps 
of each image by overlaying the Rab and marker channels. The total number 
of vesicles and the number showing overlap between both markers were 
tallied. All ﬁ  xed cell microscopy was performed at room temperature. For 
live cell microscopy, BS-C-1 cells on glass coverslips were observed 16–20 h 
after transfection at 37°C on a temperature-controlled stage of an inverted 
microscope (Diaphot-300; Nikon) equipped with a cooled CCD camera 
(NDE/CCD; Princeton Instruments), Plan Apo 60×, 1.40 NA, and 100×, 
1.40 NA, oil objectives, and using MetaMorph software (Molecular 
Devices); images were analyzed using Photoshop (Adobe). Dual CFP/YFP 
ﬁ  lters were obtained from Chroma Technology Corp. CFP- or YFP-tagged 
wild-type Rabs or CFP-Golgi (CLONTECH Laboratories, Inc.) were used as 
organelle markers.
Analysis of Rab chimera membrane association
HeLa cells on 100-mm dishes were transfected for expression of Rab 
fusion proteins with GFP, CFP, or YFP. After 23 h, cells were washed three 
times with 10 ml of phosphate buffered saline, and then two times with 
10 ml ice-cold HM buffer (25 mM Hepes, pH 7.4, and 2.5 mM Mg(OAc)2). 
Cells were swollen on ice for 5 min, washed gently with 5 ml SEAT buffer 
(10 mM ethanolamine, 10 mM acetic acid, 1 mM EDTA, and 0.25 M 
  sucrose) leaving  0.5 ml of buffer, and then scraped off of the plate with 
a rubber policeman and transferred to microfuge tubes. Protease inhibitor 
cocktail (Complete EDTA-Free; Roche) and 0.1 M PMSF were added to 
each sample. Lysates were passed through a 27-gauge needle 20 times and 
spun for 20 min at 341,000 g and 4°C in a rotor (TLA-100.1; Beckman 
Coulter). Pellets and supernatants were analyzed by SDS-PAGE and an 
anti-GFP Western blot.
Measurement of Rab activity
Rab nucleotide–binding activity was performed according to Shapiro et al. 
(1993), with minor changes. Rabs (200 nM) were incubated in 50 mM 
Hepes, pH 7.5, 150 mM KCl, 2 mM EDTA, 1 mM MgCl2, 0.1% BSA, and 
2 μM [
35S]GTPγS (4 nCi/μl) for 45 min at 25°C in 50 μl of extract. Reac-
tions were in triplicate; 40-μl samples were removed, diluted with 3 ml of 
ice-cold wash buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 25 mM 
MgCl2) and passed through 24-mm HA ﬁ  lters. Filters were washed three 
times with 3 ml of wash buffer, dried, and counted in scintillation ﬂ  uid.JCB • VOLUME 173 • NUMBER 6 • 2006  926
Online supplemental material
Fig. S1 shows deconvolution microscopic localizations of Rab9/5 and 
Rab9/1 in ﬁ   xed HeLa cells. Fig. S2 shows deconvolution microscopic 
  localizations of Rab5/9 and Rab5 in ﬁ   xed HeLa cells. Fig. S3 shows 
  deconvolution microscopic localizations of Rab1/9 and Rab1 in ﬁ  xed 
HeLa cells. Fig. S4 shows p40 is not a key effector for Rab9 localization. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200510010/DC1.
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